Brought to you by 
GSK to get siRNA respiratory therapies from Sirna
06 Apr 2006
Executive Summary
In a multi-year deal, Sirna Therapeutics (treatments based on RNA interference) will provide GlaxoSmithKline with short interfering RNA (siRNA) formulations for the treatment of respiratory diseases such as asthma and COPD.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK to get siRNA respiratory therapies from Sirna
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice